DE69213067D1 - Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen - Google Patents

Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen

Info

Publication number
DE69213067D1
DE69213067D1 DE69213067T DE69213067T DE69213067D1 DE 69213067 D1 DE69213067 D1 DE 69213067D1 DE 69213067 T DE69213067 T DE 69213067T DE 69213067 T DE69213067 T DE 69213067T DE 69213067 D1 DE69213067 D1 DE 69213067D1
Authority
DE
Germany
Prior art keywords
production
alpha
beta unsaturated
ketolactones
unsaturated ketolactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69213067T
Other languages
English (en)
Other versions
DE69213067T2 (de
Inventor
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of DE69213067D1 publication Critical patent/DE69213067D1/de
Publication of DE69213067T2 publication Critical patent/DE69213067T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE69213067T 1991-04-04 1992-04-03 Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen Expired - Fee Related DE69213067T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (2)

Publication Number Publication Date
DE69213067D1 true DE69213067D1 (de) 1996-10-02
DE69213067T2 DE69213067T2 (de) 1997-01-16

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69213067T Expired - Fee Related DE69213067T2 (de) 1991-04-04 1992-04-03 Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen

Country Status (11)

Country Link
US (1) US5229529A (de)
EP (1) EP0507625B1 (de)
JP (1) JPH089608B2 (de)
KR (1) KR970003125B1 (de)
AT (1) ATE141921T1 (de)
CA (1) CA2064481C (de)
DE (1) DE69213067T2 (de)
DK (1) DK0507625T3 (de)
ES (1) ES2093776T3 (de)
GR (1) GR3020903T3 (de)
TW (1) TW197439B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189216T1 (de) * 1992-09-30 2000-02-15 R Tech Ueno Ltd Verfahren zur herstellung von alpha, beta- ungesättigten ketonen
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
WO2002072150A2 (en) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
ATE519511T1 (de) 2006-06-30 2011-08-15 Cook Inc Verfahren zur herstellung und modifizierung von taxan-beschichtungen für implantierbare medizinische vorrichtungen
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EP2429982A4 (de) 2009-01-22 2012-09-12 Apotex Pharmachem Inc Verfahren zur herstellung von lubiproston und zwischenprodukte daraus
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
PT3300745T (pt) 2013-02-15 2019-11-27 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
PT3463308T (pt) 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022527860A (ja) 2019-04-02 2022-06-06 ケンジョッケティ バイオテクノロジー,インク. 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
US20230002740A1 (en) 2019-12-12 2023-01-05 Ignite Immunotherapy, Inc Variant oncolytic vaccinia virus and methods of use thereof
BR112022013870A2 (pt) 2020-01-29 2022-09-13 Kenjockety Biotechnology Inc Anticorpos anti-mdr1 e usos dos mesmos
JP2023528417A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー,インク. Abcg2排出ポンプ-がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
JP2023528416A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー,インク. 抗abcg2抗体及びそれらの使用
US20220033784A1 (en) 2020-07-14 2022-02-03 Pfizer Inc. Recombinant vaccinia virus
KR20230061429A (ko) 2020-09-02 2023-05-08 켄조케티 바이오테크놀러지 인코포레이티드 항-abcc1 항체 및 이의 용도
EP4244257A1 (de) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (codiert durch abcc4-gen) antikörper und verwendungen davon
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (de) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
DE3574470D1 (en) * 1985-09-18 1990-01-04 Upjohn Co Stereoselective reduktion.
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center (2−クロロ−3−オキソ−1−アルケニル)−ビシクロ〔3.3.0〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
AU2130288A (en) * 1987-09-04 1989-03-31 Upjohn Company, The Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
TW197439B (de) 1993-01-01
GR3020903T3 (en) 1996-11-30
DE69213067T2 (de) 1997-01-16
JPH0592965A (ja) 1993-04-16
CA2064481C (en) 1996-12-24
ATE141921T1 (de) 1996-09-15
US5229529A (en) 1993-07-20
KR970003125B1 (ko) 1997-03-14
CA2064481A1 (en) 1992-10-05
KR920019771A (ko) 1992-11-20
EP0507625A1 (de) 1992-10-07
JPH089608B2 (ja) 1996-01-31
DK0507625T3 (da) 1996-09-16
ES2093776T3 (es) 1997-01-01
EP0507625B1 (de) 1996-08-28

Similar Documents

Publication Publication Date Title
DE69213067D1 (de) Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen
DE69132318D1 (de) Verfahren zur herstellung von pyrimidinverbindungen
DE69013313T2 (de) Mehrstufenverfahren zur Herstellung von Hexafluorpropylen.
DE69008326D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
DE69010171D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
IL80391A (en) Process for the preparation of decabromodiphenyl ether with improved thermal stability
ES2060570T1 (es) Procedimiento para la preparacion de acidos alfa-arilpropionicos.
DE69221673D1 (de) Herstellung von Bis(fluormethyl)äther und von Difluormethan
ES2045215T3 (es) (+)-o (+)-1-(2-n-aminoetil sustituido) -1-metil-7-metoxi-1,2,3,4-tetrahidronaftaleno, y procedimiento para su produccion.
ATE49185T1 (de) Verfahren zur herstellung von halogen-magnesium- alanat und dessen verwendung.
AU2857492A (en) Improved fish production
ES2145060T3 (es) Procedimiento para producir una cetona alfa, beta insaturada.
DE69914493D1 (de) Verfahren zur herstellung von 2-hydroxy-6-trifluormethylpyridin
DE59405089D1 (de) Verfahren zur Herstellung von 4,5-Difluorbenzaldehyden
ATE41141T1 (de) Verfahren zur herstellung von trichlorphenol.
ES2118828T3 (es) Procedimiento para la obtencion de acidos 2,5-dihidroxifenilaceticos.
ATE106858T1 (de) Verfahren zur herstellung von halogenacetalen aus enaminen.
ATE10936T1 (de) Verfahren zur herstellung von 2-alkoxy-4aminopyrimidinen.
ATE59375T1 (de) Verfahren zur herstellung von polyenaldehyden.
ES2075641T3 (es) Procedimiento para la purificacion de la pseudo-ionona.
GB2097792B (en) 1,3-dihydro-2h-imidazol-2-ones
ES2053630T3 (es) Procedimiento para preparar naproxen.
DK93884A (da) Fremgangsmaade til fremstilling af 1,5-dibeskyttede-1,5,10-triazadecaner, mellemprodukter derfor samt disses fremstilling
DE68913299D1 (de) Verfahren zur Herstellung von 1,1,3,3-Tetramethylbutylhydroperoxid.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee